Abstract:Diffuse Midline Glioma (DMG) are fatal pediatric brain tumors with no effective systemic therapies. We leveraged network-based methodologies to dissect tumor heterogeneity, discover Master Regulators (MR) representing pharmacologically accessible vulnerabilities of distinct DMG cell states, and validated candidate MR-reversing drugs predicted by the NYS CLIA-certified OncoTarget and OncoTreat algorithms (Cancer Discov 2023) in vivo. We first interrogated single cell DMG regulatory networks generated by ARACNe (Nat Genet 2005) with publicly available gene expression signatures from 3,039 tumor cells across 6 patients using VIPER (Nat Genet 2016) to infer single cell regulatory protein activity. Clustering of cells by protein activity defined 7 patient-independent cell states with distinct MR profiles reflecting known glial lineage markers (OPC-like-S1, OPC-like-S2, OC-like-S1, OC-like-S2, Cycling, AC-like, and AC/OPC-like). We then generated drug-induced differential protein activity from RNAseq profiles following perturbation with 372 oncology drugs in two DMG cell lines that together recapitulate the MR signatures of the cell states and used this to identify drugs that invert tumor MR activity profiles using OncoTreat. Candidate drugs predicted by OncoTarget (inhibitors of individual MRs) and OncoTreat were distinct across the cell states, and we selected five drugs targeting the OPC/cycling-like cells (Trametinib, Dinaciclib, Avapritinib, Mocetinostat, and Etoposide), and four drugs targeting the AC-like cells (Ruxolitinib, Venetoclax, Napabucasin, Larotrectonib) for further validation as these states comprised most tumor cells across patients. We generated single-cell RNAseq for 95,687 cells after 5 days of treatment with either vehicle control (n = 4) or candidate drug (n = 2-3/drug) in subcutaneous SU-DIPG-17 mouse models. We show this model recapitulates cell states seen in patients and confirm reduction in tumor growth and significant depletion of either OPC/cycling-like cells or AC-like cells in line with our drug predictions for 8/9 candidate drugs. We then treated a syngeneic (DIPG4423) orthotopic DMG model with each drug and demonstrate significant differences in survival with Avapritinib, Dinaciclib, and Trametinib. Notably, the combination of drugs targeting OPC/cycling-like and AC-like cells (i.e. Trametinib+Ruxolitinib and Avapritinib+Venetoclax) showed significantly lower tumor volumes after 2 weeks of treatment as compared to vehicles or each drug alone, and significant survival differences for some combinations. This work provides a precision medicine platform to nominate much-needed novel drug combinations addressing DMG tumor heterogeneity for further study to improve outcomes in this devastating disease. Citation Format: Ester Calvo Fernandez, Lorenzo Tomassoni, Xu Zhang, Aleksandar Obradovic, Pasquale Laise, Aaron T. Griffin, Lukas Vlahos, Junqiang Wang, Hanna E. Minns, Diana V. Morales, Christian Simmons, Matthew Gallito, Hong-Jian Wei, Zhiguo Zhang, Robyn Gartrell, Luca Szalontay, Stergios Zacharoulis, Cheng-Chia Wu, Andrea Califano, Jovana Pavisic. Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5460.

OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma

Targeting BCAT1 Combined with α-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma

Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems

Myeloid cells coordinately induce glioma cell-intrinsic and cell-extrinsic pathways for chemoresistance via GP130 signaling

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation

Dddr-41. A Genome-Wide Crispr/Cas9 Screen In Glioblastoma Stem Cells Unveils Synthetic Lethal Interactions And Resistance Mechanisms Of Jin001, A Blood-Brain Barrier-Penetrant Hsp90 Inhibitor

Abstract 5841: A genome wide CRISPR-Cas9 screen identifies mediators of resistance to dual PI3K/mTOR inhibition in glioblastoma multiforme

Abstract 356: Pre-clinical investigations utilizing Bcl2 inhibitors in glioblastoma

Abstract 5846: Inhibiting elements of the proteasome recovery pathway sensitizes glioblastoma to proteasome inhibitors

Dddr-42. Leveraging Genome-Wide Crispr/Cas9 Knockout Drug Screens To Identify Sensitizers For Proteosome Inhibitors In Glioblastoma

DN-01 * BYPASSING GLIOBLASTOMA RESISTANCE TO EGFR INHIBITORS BY SYNTHETIC LETHALITY

Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma

Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma

Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma

Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma

Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma

A Multi-Orthogonal Strategy For Targeting Egfrviii Expressing Glioblastomas

Abstract 3478: A multi-orthogonal strategy for targeting EGFRvIII expressing glioblastomas

Abstract 5460: Discovery and validation of effective combination therapies targeting cell state-specific master regulator vulnerabilities by network-based protein activity inference in diffuse midline glioma

Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling